MX382693B - Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. - Google Patents

Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.

Info

Publication number
MX382693B
MX382693B MX2018000089A MX2018000089A MX382693B MX 382693 B MX382693 B MX 382693B MX 2018000089 A MX2018000089 A MX 2018000089A MX 2018000089 A MX2018000089 A MX 2018000089A MX 382693 B MX382693 B MX 382693B
Authority
MX
Mexico
Prior art keywords
methods
factor viii
polypeptides
hybrid
same
Prior art date
Application number
MX2018000089A
Other languages
English (en)
Inventor
Alan J Bitonti
Alvin Luk
Byron Mckinney
Glenn Pierce
Haiyan Jiang
Jennifer A Dumont
Jurg Sommer
Karen Nugent
Lian Li
Matt Ottmer
Robert Peters
Susan Low
Original Assignee
Biogen Hemophilia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Hemophilia Inc filed Critical Biogen Hemophilia Inc
Publication of MX382693B publication Critical patent/MX382693B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para administrar el Factor VIII; métodos para administrar polipéptidos quiméricos e híbridos que comprenden el Factor VIII; polipéptidos quiméricos e híbridos que comprenden el Factor VIII; polinucleótidos que codifican tales polipéptidos quiméricos e híbridos; células que comprenden tales polipéptidos; y métodos para producir tales polipéptidos quiméricos e híbridos que usan tales células.
MX2018000089A 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. MX382693B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US28505409P 2009-12-09 2009-12-09
US30159210P 2010-02-04 2010-02-04
US36306510P 2010-07-09 2010-07-09
US37311310P 2010-08-12 2010-08-12
US41092910P 2010-11-07 2010-11-07
US41967610P 2010-12-03 2010-12-03
PCT/US2010/059136 WO2011069164A2 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX382693B true MX382693B (es) 2025-03-13

Family

ID=44115536

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012006347A MX336830B (es) 2009-12-06 2010-12-06 Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.
MX2018000089A MX382693B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
MX2016000039A MX353233B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012006347A MX336830B (es) 2009-12-06 2010-12-06 Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016000039A MX353233B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.

Country Status (30)

Country Link
US (5) US9050318B2 (es)
EP (4) EP2506868B1 (es)
JP (8) JP5903048B2 (es)
KR (1) KR101770849B1 (es)
CN (1) CN102791285A (es)
AU (6) AU2010325787B2 (es)
BR (1) BR112012013502A2 (es)
CA (2) CA2782424C (es)
CO (1) CO6561782A2 (es)
CY (2) CY1119919T1 (es)
DK (1) DK2506868T3 (es)
EA (2) EA025416B1 (es)
ES (2) ES2659888T3 (es)
HR (2) HRP20180135T1 (es)
HU (1) HUE036233T2 (es)
IL (2) IL220204B (es)
LT (1) LT2506868T (es)
ME (1) ME02964B (es)
MX (3) MX336830B (es)
MY (1) MY159135A (es)
NO (1) NO2506868T3 (es)
NZ (2) NZ600709A (es)
PL (2) PL3326643T3 (es)
PT (2) PT2506868T (es)
RS (1) RS56957B1 (es)
SG (3) SG181130A1 (es)
SI (1) SI2506868T1 (es)
SM (1) SMT201800099T1 (es)
WO (1) WO2011069164A2 (es)
ZA (1) ZA201204874B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
BR112012013502A2 (pt) * 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
DK2729161T3 (en) * 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
WO2013016454A1 (en) * 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
CN111499761A (zh) * 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
BR112014017111A8 (pt) * 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
CN111548418A (zh) * 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
EP3521321B1 (en) 2012-04-11 2020-11-04 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
AU2013290173B2 (en) * 2012-07-11 2018-02-15 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
DK2956477T4 (da) * 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
EP3666283B1 (en) * 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
US10364288B2 (en) 2013-05-24 2019-07-30 Biogen Ma Inc. Anti-GPIIB/IIIA antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
KR102296042B1 (ko) * 2013-06-20 2021-08-31 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법의 제공
HK1223302A1 (zh) * 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
WO2015015448A2 (en) 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10325687B2 (en) * 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
PH12016501323B1 (en) 2014-01-10 2022-04-29 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
US11602525B2 (en) 2014-04-25 2023-03-14 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CN108064282A (zh) 2014-10-14 2018-05-22 哈洛齐梅公司 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
MY197302A (en) 2016-04-15 2023-06-12 Takeda Pharmaceuticals Co Method and apparatus for providing a pharmacokinetic drug dosing regimen
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
CN118027185A (zh) 2016-08-05 2024-05-14 免疫医疗有限责任公司 抗o2抗体及其用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
KR20190064636A (ko) 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
CN110520149A (zh) * 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
EP3576762A1 (en) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
MX2020013036A (es) 2018-06-05 2021-02-26 Amgen Inc Modulacion de la fagocitosis celular dependiente de anticuerpos.
CA3110530A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
AU2019393880A1 (en) 2018-12-06 2021-07-15 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor IX
JP2022537200A (ja) 2019-06-19 2022-08-24 バイオベラティブ セラピューティクス インコーポレイテッド 血友病および低骨ミネラル密度を処置するための方法および組成物
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
JP2025515356A (ja) * 2022-04-28 2025-05-14 ジョイント・ストック・カンパニー “バイオキャド” Ｆｖｉｉｉ－ｂｄｄおよび異種シグナルペプチドに基づく融合タンパク質をコードする単離された核酸
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
JP2003530838A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
CA2436807A1 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
PT1624891E (pt) * 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004255553B2 (en) 2003-06-19 2009-08-20 Genentech, Inc. Compositions and methods for treating coagulation related disorders
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7632921B2 (en) 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2863222A1 (en) 2006-03-06 2015-04-22 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
EP2010222A1 (en) * 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
CN103497247A (zh) * 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
DK2729161T3 (en) 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
BR112014017111A8 (pt) * 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
EP3666283B1 (en) * 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Also Published As

Publication number Publication date
SG10201907152YA (en) 2019-09-27
EP4382170A3 (en) 2024-09-04
JP2020019821A (ja) 2020-02-06
AU2021202912B2 (en) 2024-08-01
JP6641340B2 (ja) 2020-02-05
PL3326643T3 (pl) 2021-10-25
EP3326643A1 (en) 2018-05-30
JP2023071969A (ja) 2023-05-23
AU2010325787A2 (en) 2013-06-06
AU2024227757A1 (en) 2024-11-21
EP3906937A1 (en) 2021-11-10
JP2013512678A (ja) 2013-04-18
CO6561782A2 (es) 2012-11-15
IL220204B (en) 2018-08-30
BR112012013502A2 (pt) 2017-01-10
EP3326643B1 (en) 2021-04-07
CA2782424A1 (en) 2011-06-09
JP6062459B2 (ja) 2017-01-18
AU2010325787B2 (en) 2016-05-12
RS56957B1 (sr) 2018-05-31
ZA201204874B (en) 2016-06-29
PT2506868T (pt) 2018-02-23
AU2016213822B2 (en) 2017-08-31
AU2017268648A1 (en) 2017-12-21
EA201691109A1 (ru) 2017-01-30
AU2019202969A1 (en) 2019-05-16
AU2016213822A1 (en) 2016-09-01
NZ600709A (en) 2015-01-30
PL2506868T3 (pl) 2018-06-29
US20220265780A1 (en) 2022-08-25
IL220204A0 (en) 2012-07-31
MX2012006347A (es) 2012-10-03
JP7244688B2 (ja) 2023-03-22
HRP20211010T1 (hr) 2021-09-17
ES2659888T3 (es) 2018-03-19
JP6385410B2 (ja) 2018-09-05
US20160199455A1 (en) 2016-07-14
KR101770849B1 (ko) 2017-09-05
HRP20180135T1 (hr) 2018-04-06
HUE036233T2 (hu) 2018-06-28
IL260769B (en) 2020-03-31
JP2025083451A (ja) 2025-05-30
SI2506868T1 (en) 2018-04-30
AU2010325787A8 (en) 2012-07-19
MX353233B (es) 2018-01-08
HK1253887A1 (en) 2019-07-05
PT3326643T (pt) 2021-07-12
MX336830B (es) 2016-02-03
KR20120129882A (ko) 2012-11-28
JP2015083608A (ja) 2015-04-30
WO2011069164A2 (en) 2011-06-09
ME02964B (me) 2018-07-20
EP2506868B1 (en) 2017-11-15
AU2010325787A1 (en) 2012-07-12
MY159135A (en) 2016-12-15
US20190262429A1 (en) 2019-08-29
US9241978B2 (en) 2016-01-26
JP2022051964A (ja) 2022-04-01
EA038618B1 (ru) 2021-09-23
SG10201408049SA (en) 2015-02-27
EA201290443A1 (ru) 2013-06-28
EA025416B1 (ru) 2016-12-30
CA2782424C (en) 2021-07-27
US9050318B2 (en) 2015-06-09
JP2017025098A (ja) 2017-02-02
EP2506868A2 (en) 2012-10-10
CA3121739A1 (en) 2011-06-09
US20130108629A1 (en) 2013-05-02
EP4382170A2 (en) 2024-06-12
US20130274194A1 (en) 2013-10-17
JP5903048B2 (ja) 2016-04-13
AU2021202912A1 (en) 2021-06-03
AU2017268648B2 (en) 2019-01-31
CY1124888T1 (el) 2023-01-05
DK2506868T3 (da) 2018-01-29
SG181130A1 (en) 2012-07-30
ES2880038T3 (es) 2021-11-23
CY1119919T1 (el) 2018-06-27
CN102791285A (zh) 2012-11-21
JP2018024706A (ja) 2018-02-15
EP2506868A4 (en) 2013-07-24
LT2506868T (lt) 2018-02-26
NO2506868T3 (es) 2018-04-14
WO2011069164A3 (en) 2011-07-28
US11266720B2 (en) 2022-03-08
NZ703153A (en) 2015-02-27
SMT201800099T1 (it) 2018-03-08

Similar Documents

Publication Publication Date Title
MX382693B (es) Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
EA201291480A1 (ru) Фактор ix полипептиды и способы их использования
MY180714A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
PH12018501839A1 (en) St2l antagonists and methods of use
HK1213521A1 (zh) Fix多肽的應用
CR20120298A (es) Antagonistas de il-17a
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
BR112012014865A2 (pt) lentes de contato estabilizadas
CR20110642A (es) Antagonistas del receptor tipo toll 3
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования
PA8849101A1 (es) Procedimiento de preparación del hemifumarato de eplivanserina
HK1185266A (zh) 因子ix多肽及其使用方法
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors